Skip to Main Content
Table 1

Antitumor activity and toxicity of different schedules of topotecan administered i.p. in mice

Group of animalsSchedule of administrationaToxic death (%)Maximum weight loss (%)Cured mice (%)
12.5 mg/kg × 1 16.67 
2.5 mg/kg d × 5b 33.3 27 33.33 
1.25 mg/kg (d × 5)2b 16.67 12 83.33 
0.625 mg/kg (d × 5)4b 100 
0.312 mg/kg (d × 5)8b 0.15 50 
0.156 mg/kg (d × 5)16b 33.33 
1.25 mg/kg (d × 5)q2wc 18 16.67 
0.625 mg/kg [(d × 5)q2w]2c 50 
Group of animalsSchedule of administrationaToxic death (%)Maximum weight loss (%)Cured mice (%)
12.5 mg/kg × 1 16.67 
2.5 mg/kg d × 5b 33.3 27 33.33 
1.25 mg/kg (d × 5)2b 16.67 12 83.33 
0.625 mg/kg (d × 5)4b 100 
0.312 mg/kg (d × 5)8b 0.15 50 
0.156 mg/kg (d × 5)16b 33.33 
1.25 mg/kg (d × 5)q2wc 18 16.67 
0.625 mg/kg [(d × 5)q2w]2c 50 
a

Topotecan treatment began 3 days after tumor implantation.

b

Topotecan was administered i.p. 5 days/week, for 1, 2, 4, 8, or 16 consecutive weeks.

c

Topotecan was administered i.p. 5 days/week every other week for a total of 4 or 8 weeks.

Close Modal

or Create an Account

Close Modal
Close Modal